Methylmercury-induced inhibition of paraoxonase-1 (PON1) - Implications for cardiovascular risk

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 77, Issue 17, 2014, Pages 1004-1023

  Ginsberg, G ^a   Sonawane, B ^b   Nath, R ^b   Lewandowski, P ^c  

^a CDC   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; METHYLMERCURY;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; ENZYME INACTIVATION; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, OMEGA-3; FISHES; FOOD CONTAMINATION; HUMANS; LIPID METABOLISM; MEAT; METHYLMERCURY COMPOUNDS; MICE; REACTIVE OXYGEN SPECIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84905389273     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2014.919837     Document Type: Article

References (110)

1. Agency for Toxic Substances and Disease Registry. 2013. Addendum to the toxicological profile for mercury (alkyl and dialkyl compounds). http://www.atsdr.cdc.gov/toxprofiles/mercury-organic-addendum.pdf. (accessed December 2, 2013).
2. Aguado, A., Galán, M., Zhenyukh, O., Wiggers, G. A., Roque, F. R., Redondo, S., Peçanha, F., Martín, A., Fortuño, A., Cachofeiro, V., Tejerina, T., Salaices, M., and, Briones, A. M. 2013. Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. Toxicol. Appl. Pharmacol. 268: 188-200.
3. Anderson, H. A., Hanrahan, L. P., Smith, A., Draheim, L., Kanarek, M., and, Olsen, J. 2004. The role of sport-fish consumption advisories in mercury risk communication: A 1998-1999 12-state survey of women age 18-45. Environ. Res. 95: 315-324.
4. Araoud, M., Neffeti, F., Douki, W., Najjar, M. F., and, Kenani, A. 2010. Paraoxonase 1 correlates with butyrylcholinesterase and gamma glutamyl transferase in workers chronically exposed to pesticides. J. Occup. Health 52: 383-388.
5. Aslan, M., Nazligul, Y., Horoz, M., Bolukbas, C., Bolukbas, F. F., Gur, M., Celik, H., and, Erel, O. 2008. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis 196: 270-274.
6. Aviram, M., Billecke, S., Sorenson, R., Bisgaier, C., Newton, R., Rosenblat, M., Erogul, J., Hsu, C., Dunlop, C., and, La Du, B. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
7. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C. L., Newton, R. S., and, La Du, B. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol. Med. 26: 892-904.
8. Ayotte, P., Carrier, A., Ouellet, N., Boiteau, V., Abdous, B., Sidi, E. A., Château-Degat, M. L., Dewailly, É. (2011). Relation between methylmercury exposure and plasma paraoxonase activity in inuit adults from Nunavik. Environ. Health Perspect. 119: 1077-1083.
9. Bagchi, D., Bagchi, M., Hassoun, E. A., and, Stohs, S. J. 1995. In vitro and in vivo generation of reactive oxygen species, DNA damage and lactate dehydrogenase leakage by selected pesticides. Toxicology 104: 129-140.
10. Banerjee, I. 2010. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: A meta-analysis. Eur. J. Epidemiol. 25: 449-458.
11. Bayrak, A., Bayrak, T., Demirpençe, E., and, Kilinç, K. 2011. Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 879: 49-55.
12. Bayrak, A., Bayrak, T., Tokgözoglu, S. L., Volkan-Salanci, B., Deniz, A., Yavuz, B., Alikasifoglu, M., and, Demirpençe, E. 2012. Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis. J. Atheroscler. Thromb. 19: 376-384.
13. Bayram, F., Kocer, D., Ozsan, M., and, Muhtaroglu, S. 2012. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: Relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol. Endocrinol. 28: 497-501.
14. Bellinger, D. C. 2007. Interpretation of small effect sizes in occupational and environmental neurotoxicology: individual versus population risk. Neurotoxicology 28: 245-251.
15. Bhattacharyya, T., Nicholls, S. J., Topol, E. J., Zhang, R., Yang, X., Schmitt, D., Fu, X., Shao, M., Brennan, D. M., Ellis, S. G., Brennan, M. L., Allayee, H., Lusis, A. J., and, Hazen, S. L. 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J. Am. Med. Assoc. 299: 1265-1276.
16. Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., La Du, B. N. 2000. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28: 1335-1342.
17. Chang, M. H., Yesupriya, A., Ned, R. M., Mueller, P. W., and, Dowling, N. F. 2010. Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey. BMC Med. Genet. 11: 62.
18. Cherki, M., Berrougui, H., Isabelle, M., Cloutier, M., Koumbadinga, G. A., and, Khalil, A. 2007. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp. Gerontol. 42: 815-824.
19. Choi, A. L., Weihe, P., Budtz-Jørgensen, E., Jørgensen, P. J., Salonen, J. T., Tuomainen, T. P., Murata, K., Nielsen, H. P., Petersen, M. S., Askham, J., and, Grandjean, P. 2009. Methylmercury exposure and adverse cardiovascular effects in Faroese whaling men. Environ. Health Perspect. 117: 367-372.
20. Counter, S. A., Buchanan, L. H., Ortega, F., and, Laurell, G. 2002. Elevated blood mercury and neuro-otological observations in children of the Ecuadorian gold mines. J. Toxicol. Environ. Health A 65: 149-163.
21. Cole, T. B., Li, W. F., Richter, R. J., Furlong, C. E., and, Costa, L. G. 2002. Inhibition of paraoxonase (PON1) by heavy metals. Toxicol. Sci. 66 (. suppl. 1): 312 [Abstract].
22. Costa, L. G., Cole, T. B., Jarvik, G. P., and, Furlong, C. E. 2003. Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 54: 371-392.
23. Costa, L. G., Vitalone, A., Cole, T. B., and, Furlong, C. E. 2005. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 69: 541-550.
24. Costa, L. G., Giordano, G., and, Furlong, C. E. 2011. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochem. Pharmacol. 81: 337-344.
25. Dahabreh, I. J., Kitsios, G. D., Kent, D. M., and, Trikalinos, T. A. 2010. Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet. Med. 12: 606-615.
26. Deakin, S. P., and, James, R. W. 2004. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 107: 435-447.
27. Debord, J., Bollinger, J. C., Merle, L., and, Dantoine, T. 2003. Inhibition of human serum arylesterase by metal chlorides. J. Inorg. Biochem. 94: 1-4.
28. Dilek, E. B., Küfrevioǧlu, O. I., and, Beydemir, S. 2013. Impacts of some antibiotics on human serum paraoxonase 1 activity. J. Enzyme Inhib. Med. Chem. 28: 758-764.
29. Efrat, M., and, Aviram, M. 2010. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis-A protective role for HDL phospholipids. Adv. Exp. Med. Biol. 660: 153-166.
30. Ferré, N., Camps, J., Cabré, M., Paul, A., and, Joven, J. 2001. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50: 997-1000.
31. Ferré, N., Camps, J., Fernández-Ballart, J., Arija, V., Murphy, M. M., Marsillach, J., and, Joven, J. 2006. Longitudinal changes in serum paraoxonase-1 activity throughout normal pregnancy. Clin. Chem. Lab. Med. 44: 880-882.
32. Ferretti, G., Bacchetti, T., Saturni, L., Manzella, N., Candelaresi, C., Benedetti, A., and, Di Sario, A. 2012. Lipid peroxidation and paraoxonase-1 activity in celiac disease. J. Lipids article ID 587479.
33. Franco-Pons, N., Marsillach, J., Joven, J., Camps, J., and, Closa, D. 2008. Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis. J. Gastrointest. Surg. 12: 891-899.
34. Furlong, C. E. 2007. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J. Biochem. Mol. Toxicol. 21: 197-205.
35. Furlong, C. E., Holland, N., Richter, R. J., Bradman, A., Ho, A., and, Eskenazi, B. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics 16: 183-190.
36. Ginsberg, G. L. 2012. Cadmium risk assessment in relation to background risk of chronic kidney disease. J. Toxicol. Environ. Health A 75: 374-390.
37. Ginsberg, G. L., and, Toal, B. F. 2009. Quantitative approach for incorporating methylmercury risks and omega-3 fatty acid benefits in developing species-specific fish consumption advice. Environ. Health Perspect. 117: 267-275.
38. Gonzalvo, M. C., Gil, F., Hernández, A. F., Villanueva, E., and, Pla, A. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem. Biol. Interact. 105: 169-179.
39. Guallar, E., Sanz-Gallardo, M. I., vant Veer, P., Bode, P., Aro, A., Gómez-Aracena, J., Kark, J. D., Riemersma, R. A., Martín-Moreno, J. M., and Kok, F. J. 2002. Mercury, fish oils, and the risk of myocardial infarction. Heavy Metals and Myocardial Infarction Study Group. N. Engl. J. Med. 347: 1747-1754.
40. Gupta, N., Binu, K. B., Singh, S., Maturu, N. V., Sharma, Y. P., Bhansali, A., and, Gill, K. D. 2012. Low serum PON1 activity: An independent risk factor for coronary artery disease in North-West Indian type 2 diabetics. Gene 498: 13-19.
41. Hallgren, C. G., Hallmans, G., Jansson, J. H., Marklund, S. L., Huhtasaari, F., Schütz, A., Strömberg, U., Vessby, B., and, Skerfving, S. 2001. Markers of high fish intake are associated with decreased risk of a first myocardial infarction. Br. J. Nutr. 86: 397-404.
42. Harangi, M., Seres, I., Magyar, M. T., Csipo, I., Sipka, S., Valikovics, A., Csiba, L., Bereczki, D., and, Paragh, G. 2008. Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc. Dis. 25: 122-128.
43. Hernández, A. F., Mackness, B., Rodrigo, L., López, O., Pla, A., Gil, F., Durrington, P. N., Pena, G., Parrón, T., Serrano, J. L., and, Mackness, M. I. 2003. Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure. Hum. Exp. Toxicol. 22: 565-574.
44. Hernández, A., Gómez, M. A., Pena, G., Gil, F., Rodrigo, L., Villanueva, E., and, Pla, A. 2004. Effect of long-term exposure to pesticides on plasma esterases from plastic greenhouse workers. J. Toxicol. Environ. Health A 67: 1095-1108.
45. Hernández, A. F., Gil, F., Leno, E., López, O., Rodrigo, L., and, Pla, A. 2009. Interaction between human serum esterases and environmental metal compounds. Neurotoxicology 30: 628-635.
46. Hine, D., Mackness, B., and, Mackness, M. 2012. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life 64: 157-161.
47. Holzer, M., Trieb, M., Konya, V., Wadsack, C., Heinemann, A., Marsche, G. 2013. Aging affects high-density lipoprotein composition and function. Biochim. Biophys. Acta 1831: 1442-1448.
48. Jakubowski, H. 1999. Protein homocysteinylation: Possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13: 2277-2283.
49. Jakubowski, H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275: 3957-3962.
50. Jakubowski, H. 2008. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J. Physiol. Pharmacol. 59 (. suppl. 9): 155-167.
51. Jaouad, L., de Guise, C., Berrougui, H., Cloutier, M., Isabelle, M., Fulop, T., Payette, H., and, Khalil, A. 2006. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1s free sulfhydryl groups. Atherosclerosis 185: 191-200.
52. Jarvik, G. P., Rozek, L. S., Brophy, V. H., Hatsukami, T. S., Richter, R. J., Schellenberg, G. D., and, Furlong, C. E. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
53. Johnsson, C., Schütz, A., and, Sällsten, G. 2005. Impact of consumption of freshwater fish on mercury levels in hair, blood, urine, and alveolar air. J. Toxicol. Environ. Health A 68: 129-140.
54. Kamal, M., Fathy, M. M., Taher, E., Hasan, M., and, Tolba, M. 2011. Assessment of the role of paraoxonase gene polymorphism (Q192R) and paraoxonase activity in the susceptibility to atherosclerosis among lead-exposed workers. Ann. Saudi Med. 31: 481-487.
55. Kotur-Stevuljevic, J., Spasic, S., Stefanovic, A., Zeljkovic, A., Bogavac-Stanojevic, N., Kalimanovska-Ostric, D., Spasojevic-Kalimanovska, V., and, Jelic-Ivanovic, Z. 2006. Paraoxonase-1 (PON1) activity, but not PON1 (Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin. Chem. Lab. Med. 44: 1206-1213.
56. Kotur-Stevuljevic, J., Spasic, S., Jelic-Ivanovic, Z., Spasojevic-Kalimanovska, V., Stefanovic, A., Vujovic, A., Memon, L., and, Kalimanovska-Ostric, D. 2008. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin. Biochem. 41: 1067-1073.
57. Koubaa, N., Nakbi, A., Hammami, S., Attia, N., Mehri, S., Ben Hamda, K., Ben Farhat, M., Miled, A., and, Hammami, M. 2009. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin. Biochem. 42: 771-776.
58. Lacinski, M., Skorupski, W., Cieslinski, A., Sokolowska, J., Trzeciak, W. H., and, Jakubowski, H. 2004. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell. Mol. Biol. 50: 885-893.
59. La Du, B. N., Aviram, M., Billecke, S., Navab, M., Primo-Parmo, S., Sorenson, R. C., and, Standiford, T. J. 1999. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 119-120: 379-388.
60. Lara-Guzman, O. J., Tabares-Guevara, J. H., Leon-Varela, Y. M., Álvarez, R. M., Roldan, M., Sierra, J. A., Londoño-Londoño, J. A., and, Ramirez-Pineda, J. R. 2012. Proatherogenic macrophage activities are targeted by the flavonoid quercetin. J. Pharmacol. Exp. Ther. 343: 296-306.
61. Lemos, N. B., Angeli, J. K., Faria Tde, O., Ribeiro Junior, R. F., Vassallo, D. V., Padilha, A. S., and, Stefanon, I. 2012. Low mercury concentration produces vasoconstriction, decreases nitric oxide bioavailability and increases oxidative stress in rat conductance artery. PLoS One 7: e49005.
62. Li, W. F., Pan, M. H., Chung, M. C., Ho, C. K., and, Chuang, H Y. 2006. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ. Health Perspect. 114: 1233-1236.
63. Macharia, M., Hassan, M. S., Blackhurst, D., Erasmus, R. T., and, Matsha, T. E. 2012. The growing importance of PON1 in cardiovascular health: A review. J. Cardiovasc. Med. 13: 443-453.
64. Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., and, Mackness, M. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107: 2775-2779.
65. Mackness, M., and, Mackness, B. 2004. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important? Free Radical Biol. Med. 37: 1317-1323.
66. Mackness, M., Durrington, P., and, Mackness, B. 2004. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr. Opin. Lipidol. 15: 399-404.
67. Mackness, B., Quarck, R., Verreth, W., Mackness, M., and, Holvoet, P. 2006. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26: 1545-1550.
68. Mackness, B., Beltran-Debon, R., Aragones, G., Joven, J., Camps, J., and, Mackness, M. 2010. Human tissue distribution of paraoxonases 1 and 2 mRNA. IUBMB Life 62: 480-482.
69. Mahaffey, K. R., Sunderland, E. M., Chan, H. M., Choi, A. L., Grandjean, P., Mariën, K., Oken, E., Sakamoto, M., Schoeny, R., Weihe, P., Yan, C. H., and, Yasutake, A. 2011. Balancing the benefits of n-3 polyunsaturated fatty acids and the risks of methylmercury exposure from fish consumption. Nutr. Rev. 69: 493-508.
70. Marsillach, J., Mackness, B., Mackness, M., Riu, F., Beltrán, R., Joven, J., and, Camps, J. 2008. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radical Biol. Med. 45: 146-157.
71. Martinelli, N., Consoli, L., Girelli, D., Grison, E., Corrocher, R., and, Olivieri, O. 2013. Paraoxonases: Ancient substrate hunters and their evolving role in ischemic heart disease. Adv. Clin. Chem. 2013: 59: 65-100.
72. McCully, K. S. 2009. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann. Clin. Lab. Sci. 39: 219-232.
73. Mendes, R. H., Sirvente, R. A., Candido, G. O., Mostarda, C., Salemi, V. M., DAlmeida, V., Jacob, M. H., Ribeiro, M. F., Belló-Klein, A., Rigatto, K., and, Irigoyen, M. C. 2010. Homocysteine thiolactone induces cardiac dysfunction: Role of oxidative stress. J. Cardiovasc. Pharmacol. 55: 198-202.
74. Mozaffarian, D., and, Rimm, E. B. 2006. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. J. Am. Med. Assoc. 296: 1885-1899.
75. Mozaffarian, D., Shi, P., Morris, J. S., Grandjean, P., Siscovick, D. S., Spiegelman, D., Willett, W. C., Rimm, E. B., Curhan, G. C., and, Forman, J. P. 2012. Mercury exposure and risk of hypertension in US men and women in 2 prospective cohorts. Hypertension 60: 645-652.
76. Mozaffarian, D., Shi, P., Morris, J. S., Spiegelman, D., Grandjean, P., Siscovick, D. S., Willett, W. C., and, Rimm, E. B. 2011. Mercury exposure and risk of cardiovascular disease in two U.S. cohorts. N. Engl. J. Med. 364: 1116-1125.
77. Muniz, J. F., McCauley, L., Scherer, J., Lasarev, M., Koshy, M., Kow, Y. W., Nazar-Stewart, V., and, Kisby, G. E. 2008. Biomarkers of oxidative stress and DNA damage in agricultural workers: A pilot study. Toxicol. Appl. Pharmacol. 227: 97-107.
78. National Research Council. 2009. Science and decisions. Advancing risk assessment. Washington DC: National Academies Press.
79. Nguyen, S. D., and, Sok, D. E. 2003. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radical Res. 37: 1319-1330.
80. Park, J. D., and, Zheng, W. 2012. Human exposure and health effects of inorganic and elemental mercury. J. Prev. Med. Public Health 45: 344-352.
81. Peng, W., Zhang, C., Lv, H., Zhu, J., Zang, Y., Pang, X., Zhang, J., and, Qin, J. 2010. Comparative evaluation of the protective potentials of human paraoxonase 1 and 3 against CCl4-induced liver injury. Toxicol. Lett. 193: 159-166.
82. Permpongpaiboon, T., Nagila, A., Pidetcha, P., Tuangmungsakulchai, K., Tantrarongroj, S., and, Porntadavity, S. 2011. Decreased paraoxonase 1 activity and increased oxidative stress in low lead-exposed workers. Hum. Exp. Toxicol. 30: 1196-1203.
83. Ratcliffe, H. E., Swanson, G. M., and, Fischer, L. J. 1996. Human exposure to mercury: A critical assessment of the evidence of adverse health effects. J. Toxicol. Environ. Health 49: 221-270.
84. Rice, G. E., Hammitt, J. K., and, Evans, J. S. 2010. A probabilistic characterization of the health benefits of reducing methyl mercury intake in the United States. Environ. Sci. Technol. 44: 5216-5224.
85. Roman, H. A., Walsh, T. L., Coull, B. A., Dewailly, É., Guallar, E., Hattis, D., Mariën, K., Schwartz, J., Stern, A. H., Virtanen, J. K., and, Rice, G. 2011. Evaluation of the cardiovascular effects of methylmercury exposures: Current evidence supports development of a dose-response function for regulatory benefits analysis. Environ. Health Perspect. 119: 607-614.
86. Rozenberg, O., Rosenblat, M., Coleman, R., Shih, D. M., and, Aviram, M. 2003. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice. Free Radical Biol. Med. 34: 774-784.
87. Rozenberg, O., Shih, D. M., and, Aviram, M. 2005. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: Studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181: 9-18.
88. Salonen, J. T., Seppänen, K., Lakka, T. A., Salonen, R., and, Kaplan, G. A. 2000. Mercury accumulation and accelerated progression of carotid atherosclerosis: A population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 148: 265-273.
89. Schwartz, J. 1994. Societal benefits of reducing lead exposure. Environ. Res. 66: 105-124.
90. Selek, S., Aslan, M., Horoz, M., Gur, M., and, Erel, O. 2007. Oxidative status and serum PON1 activity in beta-thalassemia minor. Clin. Biochem. 40: 287-291.
91. Sentürk, T., Sarandöl, E., Güllülü, S., Erdinç, S., Ozdemir, B., Baran, I., and, Aydinlar, A. 2008. Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes. Acta Cardiol. 63: 361-367.
92. Shih, D. M., Gu, L., Xia, Y. R., Navab, M., Li, W. F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., and, Lusis, A. J. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
93. Sibrian-Vazquez, M., Escobedo, J. O., Lim, S., Samoei, G. K., and, Strongin, R M. 2010. Homocystamides promote free-radical and oxidative damage to proteins. Proc. Natl. Acad. Sci. USA 107: 551-554.
94. Sirivarasai, J., Kaojarern, S., Sura, T., and, Yoovathaworn, K. 2011. Biochemical, environmental, and genetic factors associated with paraoxonase (PON1) activity. Biochem. Genet. 49: 364-368.
95. Skoczyńska, A., Poreba, R., Steinmentz-Beck, A., Martynowicz, H., Affelska-Jercha, A., Turczyn, B., Wojakowska, A., and, Jedrychowska, I. 2009. The dependence between urinary mercury concentration and carotid arterial intima-media thickness in workers occupationally exposed to mercury vapour. Int. J. Occup. Med. Environ. Health 22: 135-142.
96. Soltaninejad, K., and, Abdollahi, M. 2009. Current opinion on the science of organophosphate pesticides and toxic stress: A systematic review. Med. Sci. Monit. 15: RA75-RA90.
97. Sözmen, E. Y., Mackness, B., Sözmen, B., Durrington, P., Girgin, F. K., Aslan, L., and, Mackness, M. 2002. Effect of organophosphate intoxication on human serum paraoxonase. Hum. Exp. Toxicol. 21: 247-252.
98. Sözmen, B., Peker, S., Kaya, U., Erkan, M., and, Sözmen, E. Y. 2007. Markers of long-term exposure to organophosphorus pesticides in farmers who work in viniculture and tobacco production in Turkey. Toxicol. Mech. Methods 17: 379-384.
99. Swardfager, W., Herrmann, N., Cornish, S., Mazereeuw, G., Marzolini, S., Sham, L., and, Lanctôt, K. L. 2012. Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis. Am. Heart J. 163: 666-676.
100. Sweet, L. I., and, Zelikoff, J. T. 2001. Toxicology and immunotoxicology of mercury: A comparative review in fish and humans. J. Toxicol. Environ. Health B 4: 161-205.
101. Tang, W. H., Wu, Y., Mann, S., Pepoy, M., Shrestha, K., Borowski, A. G., and, Hazen, S. L. 2011. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ. Heart Fail. 4: 259-264.
102. Tang, W. H., Hartiala, J., Fan, Y., Wu, Y., Stewart, A. F., Erdmann, J., Kathiresan, S., The CARDIoGRAM Consortium, Roberts, R., McPherson, R., Allayee, H., and, Hazen, S. L. 2012. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 32: 2803-2812.
103. U.S. Environmental Protection Agency. 2001. IRIS summary for methyl mercury. http://www.epa.gov/iris/subst/0073.htm. (accessed October 24, 2012).
104. Vassallo, D. V., Simões, M. R., Furieri, L. B., Fioresi, M., Fiorim, J., Almeida, E. A., Angeli, J. K., Wiggers, G. A., Peçanha, F. M., and, Salaices M. 2011. Toxic effects of mercury, lead and gadolinium on vascular reactivity. Braz. J. Med. Biol. Res. 44: 939-946.
105. Virtanen, J. K., Rissanen, T. H., Voutilainen, S., and, Tuomainen, T. P. 2007. Mercury as a risk factor for cardiovascular diseases. J. Nutr. Biochem. 18: 75-85.
106. Vos, E. 2008. Homocysteine levels, paraoxonase 1 (PON1) activity, and cardiovascular risk. J. Am. Med. Assoc. 300: 168-169.
107. Wang, M., Lang, X., Zou, L., Huang, S., and, Xu, Z. 2011. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 case-control studies. Atherosclerosis 214: 377-385.
108. Xue, J., Zartarian, V. G., Liu, S. V., and, Geller, A. M. 2012. Methyl mercury exposure from fish consumption in vulnerable racial/ethnic populations: probabilistic SHEDS-Dietary model analyses using 1999-2006 NHANES and 1990-2002 TDS data. Sci. Total Environ. 414: 373-379.
109. Yoshida, H., and, Kisugi, R. 2010. Mechanisms of LDL oxidation. Clin. Chim. Acta 411: 1875-1882.
110. Zhang, C., Peng, W., Wang, M., Zhu, J., Zang, Y., Shi, W., Zhang, J., and, Qin, J. 2010. Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. Gene Ther. 17: 626-633.